Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae (TEMO-BLSE)

Centre Hospitalier Annecy Genevois

Status: Completed

Conditions: Urinary Tract Infection Bacterial

Treatments: Other: Any intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04671290

19-10

Details and patient eligibility

About

To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI.

Full description

Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were enrolled in a multicenter retrospective case-control study. Cases were treated with temocillin ≥50% of the effective antibiotic therapy duration. Control exclusively received carbapenem over the effective antibiotic therapy duration.

Enrollment: 144 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults
• Diagnosis of UTI defined by at least two of the following symptoms :chills,temperature >38°C (fever), flank or pelvic pain, nausea or vomiting, dysuria, urinary frequency, or urinary urgency, costovertebral angle tenderness on physical examination
• Positive urine culture with ≥ 103 CFU/mL of a single strain of ESBL-E
• Confirmed ESBL-producing enterobacteriaceae (ESBL-E) susceptible to carbapenems

Exclusion criteria

• Multibacterial infection
• Opposition to data collection according to GDPR

Trial design

144 participants in 2 patient groups

Control

Description:

Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides).

Treatment:

Other: Any intervention

Cases

Description:

Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides).

Treatment:

Other: Any intervention